KalVista Pharmaceuticals, Inc.
KALV
$19.56
-$1.30-6.23%
NASDAQ
| 12/31/2025 | 09/30/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 11.91% | -40.93% | -13.44% | -11.48% | -23.36% |
| Total Depreciation and Amortization | 63.62% | 14.15% | -12.40% | -12.50% | -14.39% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 29.52% | 16.19% | -4.82% | -42.25% | 126.26% |
| Change in Net Operating Assets | -130.85% | -6.29% | -27.19% | -2.27% | 6,537.86% |
| Cash from Operations | 29.25% | -4.09% | -62.76% | -71.36% | -31.92% |
| Capital Expenditure | -2,014.17% | -981.82% | -943.86% | -676.19% | 37.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 134.02% | 128.27% | 140.30% | 150.40% | -327.55% |
| Cash from Investing | 181.95% | 156.21% | 211.84% | 207.44% | -190.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -98.00% | -40.47% | -40.55% | -37.09% | 25,308.77% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -75.75% | 125.82% | 125.82% | 84.55% | 49,351.00% |
| Cash from Financing | -64.79% | 16.90% | 17.22% | 5.98% | 52,244.08% |
| Foreign Exchange rate Adjustments | 41.83% | 937.02% | 510.00% | 284.01% | -12.61% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -70.66% | 618.39% | 630.24% | 510.99% | 333.71% |